Header Logo

Connection

WAYNE GOODMAN to Male

Back to Details
This is a "connection" page, showing publications WAYNE GOODMAN has written about Male.
WAYNE GOODMAN
Connection Strength
1.312
Male
  1. Deep Brain Stimulation for Obsessive-Compulsive Disorder: Optimal Stimulation Sites. Biol Psychiatry. 2024 Jul 15; 96(2):101-113.
    View in: PubMed
    Score: 0.038
  2. Impact of the COVID-19 pandemic on exposure and response prevention outcomes in adults and youth with obsessive-compulsive disorder. Psychiatry Res. 2021 01; 295:113597.
    View in: PubMed
    Score: 0.031
  3. Psychiatric Diagnoses and Medications for Hurricane Harvey Sheltered Evacuees. Community Ment Health J. 2019 10; 55(7):1099-1102.
    View in: PubMed
    Score: 0.027
  4. High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology. 2019 01; 44(2):390-398.
    View in: PubMed
    Score: 0.026
  5. Meeting the Mental Health Needs of Hurricane Harvey Evacuees. Am J Psychiatry. 2018 Jan 01; 175(1):13-14.
    View in: PubMed
    Score: 0.025
  6. Altered olfactory processing and increased insula activity in patients with obsessive-compulsive disorder: An fMRI study. Psychiatry Res Neuroimaging. 2017 Apr 30; 262:15-24.
    View in: PubMed
    Score: 0.023
  7. Switching between internally and externally focused attention in obsessive-compulsive disorder: Abnormal visual cortex activation and connectivity. Psychiatry Res Neuroimaging. 2017 Jul 30; 265:87-97.
    View in: PubMed
    Score: 0.023
  8. Neural correlates of emotional response inhibition in obsessive-compulsive disorder: A preliminary study. Psychiatry Res. 2015 Nov 30; 234(2):259-64.
    View in: PubMed
    Score: 0.021
  9. The Persistence of Experience: Prior Attentional and Emotional State Affects Network Functioning in a Target Detection Task. Cereb Cortex. 2015 Sep; 25(9):3235-48.
    View in: PubMed
    Score: 0.019
  10. The anxiety severity interview for children and adolescents: an individualized repeated measure of anxiety severity. Clin Psychol Psychother. 2014 Nov-Dec; 21(6):525-35.
    View in: PubMed
    Score: 0.018
  11. Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD. Psychiatry Res. 2013 Feb 28; 205(3):253-61.
    View in: PubMed
    Score: 0.017
  12. Clinical factors associated with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Pediatr. 2012 Feb; 160(2):314-9.
    View in: PubMed
    Score: 0.016
  13. The role of avoidance in the phenomenology of obsessive-compulsive disorder. Compr Psychiatry. 2012 Feb; 53(2):187-94.
    View in: PubMed
    Score: 0.016
  14. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition. Psychol Assess. 2010 Jun; 22(2):223-32.
    View in: PubMed
    Score: 0.015
  15. Psychometric analysis of the Yale-Brown Obsessive-Compulsive Scale Second Edition Symptom Checklist. J Anxiety Disord. 2010 Aug; 24(6):650-6.
    View in: PubMed
    Score: 0.015
  16. Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry. 2010 Mar 15; 67(6):535-42.
    View in: PubMed
    Score: 0.014
  17. Quality of life in children and adolescents with obsessive-compulsive disorder: base rates, parent-child agreement, and clinical correlates. Soc Psychiatry Psychiatr Epidemiol. 2009 Nov; 44(11):935-42.
    View in: PubMed
    Score: 0.014
  18. Concurrent validity of the Yale-Brown Obsessive-Compulsive Scale-Symptom Checklist. J Clin Psychol. 2008 Dec; 64(12):1338-51.
    View in: PubMed
    Score: 0.013
  19. Insight in pediatric obsessive-compulsive disorder: associations with clinical presentation. Psychiatry Res. 2008 Aug 15; 160(2):212-20.
    View in: PubMed
    Score: 0.013
  20. Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2008 May; 47(5):583-592.
    View in: PubMed
    Score: 0.013
  21. Cognitive-behavioral therapy for obsessive-compulsive disorder: a non-randomized comparison of intensive and weekly approaches. J Anxiety Disord. 2008 Oct; 22(7):1146-58.
    View in: PubMed
    Score: 0.012
  22. Symptom dimensions and cognitive-behavioural therapy outcome for pediatric obsessive-compulsive disorder. Acta Psychiatr Scand. 2008 Jan; 117(1):67-75.
    View in: PubMed
    Score: 0.012
  23. Sleep-related problems in pediatric obsessive-compulsive disorder. J Anxiety Disord. 2008 Jun; 22(5):877-85.
    View in: PubMed
    Score: 0.012
  24. Florida Obsessive-Compulsive Inventory: development, reliability, and validity. J Clin Psychol. 2007 Sep; 63(9):851-9.
    View in: PubMed
    Score: 0.012
  25. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007 Jul; 22(4):230-7.
    View in: PubMed
    Score: 0.012
  26. Associations between miscellaneous symptoms and symptom dimensions: an examination of pediatric obsessive-compulsive disorder. Behav Res Ther. 2007 Nov; 45(11):2593-603.
    View in: PubMed
    Score: 0.012
  27. Clinical features of children and adolescents with obsessive-compulsive disorder and hoarding symptoms. Compr Psychiatry. 2007 Jul-Aug; 48(4):313-8.
    View in: PubMed
    Score: 0.012
  28. Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensive and weekly approaches. J Am Acad Child Adolesc Psychiatry. 2007 Apr; 46(4):469-478.
    View in: PubMed
    Score: 0.012
  29. Sequential cognitive-behavioral therapy for children with obsessive-compulsive disorder with an inadequate medication response: a case series of five patients. Depress Anxiety. 2007; 24(6):375-81.
    View in: PubMed
    Score: 0.012
  30. Factor-analytic study of the Yale Global Tic Severity Scale. Psychiatry Res. 2007 Jan 15; 149(1-3):231-7.
    View in: PubMed
    Score: 0.012
  31. Cognitive-behavioral therapy for PANDAS-related obsessive-compulsive disorder: findings from a preliminary waitlist controlled open trial. J Am Acad Child Adolesc Psychiatry. 2006 Oct; 45(10):1171-8.
    View in: PubMed
    Score: 0.011
  32. Deep brain stimulation in the internal capsule and nucleus accumbens region: responses observed during active and sham programming. J Neurol Neurosurg Psychiatry. 2007 Mar; 78(3):310-4.
    View in: PubMed
    Score: 0.011
  33. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder. J Psychiatr Res. 2007 Apr-Jun; 41(3-4):332-7.
    View in: PubMed
    Score: 0.011
  34. Immunology of obsessive-compulsive disorder. Psychiatr Clin North Am. 2006 Jun; 29(2):445-69.
    View in: PubMed
    Score: 0.011
  35. The children's Yale-Brown obsessive-compulsive scale: psychometric properties of child- and parent-report formats. J Anxiety Disord. 2006; 20(8):1055-70.
    View in: PubMed
    Score: 0.011
  36. Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety. 2006; 23(7):429-33.
    View in: PubMed
    Score: 0.011
  37. Reliability and validity of the Yale Global Tic Severity Scale. Psychol Assess. 2005 Dec; 17(4):486-91.
    View in: PubMed
    Score: 0.011
  38. Hope and coping in family members of patients with obsessive-compulsive disorder. J Anxiety Disord. 2006; 20(5):614-29.
    View in: PubMed
    Score: 0.011
  39. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005 Aug; 87(2-3):161-7.
    View in: PubMed
    Score: 0.011
  40. Factor analytic study of the Children's Yale-Brown Obsessive-Compulsive Scale. J Clin Child Adolesc Psychol. 2005 Jun; 34(2):312-9.
    View in: PubMed
    Score: 0.010
  41. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry. 2005 Apr-Jun; 17(2):71-5.
    View in: PubMed
    Score: 0.010
  42. Yale-Brown Obsessive Compulsive Scale: the dimensional structure revisited. Depress Anxiety. 2005; 22(1):28-35.
    View in: PubMed
    Score: 0.010
  43. Aperiodic spectral slope tracks the effects of brain state on saliency responses in the human auditory cortex. Sci Rep. 2024 12 28; 14(1):30751.
    View in: PubMed
    Score: 0.010
  44. Problematic Substance Use in Depressed Youth: Associations with Suicidal Ideation and Suicide Attempt History. J Dual Diagn. 2025 Jan-Mar; 21(1):35-48.
    View in: PubMed
    Score: 0.010
  45. Psychometric evaluation of the Children's Yale-Brown Obsessive-Compulsive Scale. Psychiatry Res. 2004 Nov 30; 129(1):91-8.
    View in: PubMed
    Score: 0.010
  46. Aperiodic (1/f) Neural Activity Robustly Tracks Symptom Severity Changes in Treatment-Resistant Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Feb; 10(2):186-194.
    View in: PubMed
    Score: 0.010
  47. Psychometric Properties of the Yale-Brown Obsessive Compulsive Scale-II Self-Report. J Psychiatr Pract. 2024 Nov 01; 30(6):421-427.
    View in: PubMed
    Score: 0.010
  48. Parent perceptions of various treatment approaches for PANS and PANDAS. J Affect Disord. 2025 Jan 15; 369:1215-1222.
    View in: PubMed
    Score: 0.010
  49. Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528.
    View in: PubMed
    Score: 0.010
  50. Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder. Nat Med. 2024 Oct; 30(10):3004-3014.
    View in: PubMed
    Score: 0.010
  51. A Low-Intensity Transcranial Focused Ultrasound Parameter Exploration Study of the Ventral Capsule/Ventral Striatum. Neuromodulation. 2025 Jan; 28(1):146-154.
    View in: PubMed
    Score: 0.010
  52. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004 Mar 01; 55(5):553-5.
    View in: PubMed
    Score: 0.010
  53. Perceived worsening of obsessive-compulsive disorder symptoms after childbirth in women and men: An understudied phenomenon. Bull Menninger Clin. 2024; 88(1):48-60.
    View in: PubMed
    Score: 0.009
  54. Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and tics. Biol Psychiatry. 2004 Jan 01; 55(1):61-8.
    View in: PubMed
    Score: 0.009
  55. Further psychometric properties of the Tourette's Disorder Scale-Parent Rated version (TODS-PR). Child Psychiatry Hum Dev. 2004; 35(2):107-20.
    View in: PubMed
    Score: 0.009
  56. Alterations in attentional processing in youth with misophonia: A phenotypical cross-comparison with anxiety patients. J Affect Disord. 2024 02 15; 347:429-436.
    View in: PubMed
    Score: 0.009
  57. Brain activation by disgust-inducing pictures in obsessive-compulsive disorder. Biol Psychiatry. 2003 Oct 01; 54(7):751-6.
    View in: PubMed
    Score: 0.009
  58. Family Accommodation in Children and Adolescents With Misophonia. Behav Ther. 2024 May; 55(3):595-604.
    View in: PubMed
    Score: 0.009
  59. Parent-Led Cognitive Behavioral Teletherapy for Anxiety in Autistic Youth: A Randomized Trial Comparing Two Levels of Therapist Support. Behav Ther. 2024 May; 55(3):499-512.
    View in: PubMed
    Score: 0.009
  60. Examining the Relationship Between Anxiety Severity and Autism-Related Challenges During Cognitive Behavioral Therapy for Children with Autism. J Autism Dev Disord. 2024 May; 54(5):1849-1856.
    View in: PubMed
    Score: 0.009
  61. Tractography-Based Modeling Explains Treatment Outcomes in Patients Undergoing Deep Brain Stimulation for Obsessive-Compulsive Disorder. Biol Psychiatry. 2024 Jul 15; 96(2):95-100.
    View in: PubMed
    Score: 0.009
  62. COVID-19-related intrusive thoughts and associated ritualistic behaviors. Bull Menninger Clin. 2023; 87(3):225-249.
    View in: PubMed
    Score: 0.009
  63. Anger Outbursts in Youth with ASD and Anxiety: Phenomenology and Relationship with Family Accommodation. Child Psychiatry Hum Dev. 2024 Oct; 55(5):1259-1268.
    View in: PubMed
    Score: 0.009
  64. The Relationship Between Adverse Childhood Experiences, Symptom Severity, Negative Thinking, Comorbidity, and Treatment Response in Youth with Obsessive-Compulsive Disorder. Child Psychiatry Hum Dev. 2024 Oct; 55(5):1201-1210.
    View in: PubMed
    Score: 0.009
  65. Intraoperative valence testing to adjudicate between ventral capsule/ventral striatum and bed nucleus of the stria terminalis target selection in deep brain stimulation for obsessive-compulsive disorder. J Neurosurg. 2023 08 01; 139(2):442-450.
    View in: PubMed
    Score: 0.009
  66. Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol. 2002 Jun; 5(2):141-5.
    View in: PubMed
    Score: 0.008
  67. Genetics of childhood disorders: XXXIV. Autoimmune disorders, part 7: D8/17 reactivity as an immunological marker of susceptibility to neuropsychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2002 Jan; 41(1):98-100.
    View in: PubMed
    Score: 0.008
  68. Long-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorder. Nat Med. 2021 12; 27(12):2154-2164.
    View in: PubMed
    Score: 0.008
  69. Progress toward analysis of D8/17 binding to B cells in children with obsessive compulsive disorder and/or chronic tic disorder. J Neuroimmunol. 2001 Nov 01; 120(1-2):146-51.
    View in: PubMed
    Score: 0.008
  70. Perceptions of Deep Brain Stimulation for Adolescents with Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol. 2021 03; 31(2):109-117.
    View in: PubMed
    Score: 0.008
  71. The Relationship of Family Accommodation with Pediatric Anxiety Severity: Meta-analytic Findings and Child, Family and Methodological Moderators. Child Psychiatry Hum Dev. 2021 02; 52(1):1-14.
    View in: PubMed
    Score: 0.008
  72. The Impact of Comorbidity on Cognitive-Behavioral Therapy Response in Youth with Anxiety and Autism Spectrum Disorder. Child Psychiatry Hum Dev. 2020 08; 51(4):625-635.
    View in: PubMed
    Score: 0.007
  73. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
    View in: PubMed
    Score: 0.007
  74. Parent-led Behavioral Intervention for a Treatment-refusing Adult With Obsessive-Compulsive Disorder With Poor Insight and Extreme Family Accommodation. J Psychiatr Pract. 2020 03; 26(2):149-152.
    View in: PubMed
    Score: 0.007
  75. Serious negative consequences associated with exposure and response prevention for obsessive-compulsive disorder: A survey of therapist attitudes and experiences. Depress Anxiety. 2020 05; 37(5):418-428.
    View in: PubMed
    Score: 0.007
  76. Stability of subclinical obsessive compulsive disorder in college students. Depress Anxiety. 2000; 11(4):180-2.
    View in: PubMed
    Score: 0.007
  77. Development and psychometric evaluation of the Mandarin Chinese version of the Yale-Brown Obsessive-Compulsive Scale - Second Edition. Braz J Psychiatry. 2019 Nov-Dec; 41(6):494-498.
    View in: PubMed
    Score: 0.007
  78. Cost-Effectiveness of Treatment Alternatives for Treatment-Refractory Pediatric Obsessive-Compulsive Disorder. J Anxiety Disord. 2020 01; 69:102151.
    View in: PubMed
    Score: 0.007
  79. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. J Anxiety Disord. 2019 12; 68:102149.
    View in: PubMed
    Score: 0.007
  80. Predictors of treatment outcome for youth receiving intensive residential treatment for obsessive-compulsive disorder (OCD). Cogn Behav Ther. 2020 07; 49(4):294-306.
    View in: PubMed
    Score: 0.007
  81. Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol Psychiatry. 1999 Jun 01; 45(11):1440-6.
    View in: PubMed
    Score: 0.007
  82. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019 11 01; 176(11):931-938.
    View in: PubMed
    Score: 0.007
  83. Chinese Therapists' Beliefs About Exposure Therapy for Anxiety and Obsessive-Compulsive Disorders. J Psychiatr Pract. 2019 05; 25(3):179-185.
    View in: PubMed
    Score: 0.007
  84. Incidence and clinical correlates of anger attacks in Chinese patients with obsessive-compulsive disorder. J Zhejiang Univ Sci B. 2019 Apr.; 20(4):363-370.
    View in: PubMed
    Score: 0.007
  85. Clinicians' perspectives of interfering behaviors in the treatment of anxiety and obsessive-compulsive disorders in adults and children. Cogn Behav Ther. 2020 01; 49(1):81-96.
    View in: PubMed
    Score: 0.007
  86. Evidence of prefrontal hyperactivation to food-cue reversal learning in adolescents with anorexia nervosa. Behav Res Ther. 2018 12; 111:36-43.
    View in: PubMed
    Score: 0.007
  87. Pharmacological risk factors associated with hospital readmission rates in a psychiatric cohort identified using prescriptome data mining. BMC Med Inform Decis Mak. 2018 09 14; 18(Suppl 3):79.
    View in: PubMed
    Score: 0.007
  88. Habenular connectivity may predict treatment response in depressed psychiatric inpatients. J Affect Disord. 2019 01 01; 242:211-219.
    View in: PubMed
    Score: 0.007
  89. Politically-focused intrusive thoughts and associated ritualistic behaviors in a community sample. J Anxiety Disord. 2018 05; 56:35-42.
    View in: PubMed
    Score: 0.006
  90. Impact of the 2016 US presidential election on OCD symptom presentation: A case illustration. J Clin Psychol. 2018 05; 74(5):750-754.
    View in: PubMed
    Score: 0.006
  91. Neural correlates of affective and non-affective cognition in obsessive compulsive disorder: A meta-analysis of functional imaging studies. Eur Psychiatry. 2017 10; 46:25-32.
    View in: PubMed
    Score: 0.006
  92. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997; 33(1):17-22.
    View in: PubMed
    Score: 0.006
  93. Six-Nine Year Follow-Up of Deep Brain Stimulation for Obsessive-Compulsive Disorder. PLoS One. 2016; 11(12):e0167875.
    View in: PubMed
    Score: 0.006
  94. Recent developments in neurobiology of obsessive-compulsive disorder. J Clin Psychiatry. 1996 Oct; 57(10):492-503.
    View in: PubMed
    Score: 0.006
  95. Resting-state functional connectivity of the human habenula in healthy individuals: Associations with subclinical depression. Hum Brain Mapp. 2016 07; 37(7):2369-84.
    View in: PubMed
    Score: 0.006
  96. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996 Mar; 11(1):21-9.
    View in: PubMed
    Score: 0.005
  97. Human habenula segmentation using myelin content. Neuroimage. 2016 Apr 15; 130:145-156.
    View in: PubMed
    Score: 0.005
  98. Subclinical obsessive-compulsive disorder in college students. Depress Anxiety. 1996-1997; 4(5):233-6.
    View in: PubMed
    Score: 0.005
  99. Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. J Psychiatr Res. 2015 Dec; 71:140-7.
    View in: PubMed
    Score: 0.005
  100. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015 Dec; 45(16):3571-80.
    View in: PubMed
    Score: 0.005
  101. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry. 1995 Aug 01; 38(3):138-49.
    View in: PubMed
    Score: 0.005
  102. Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response. PLoS One. 2015; 10(7):e0133591.
    View in: PubMed
    Score: 0.005
  103. Who qualifies for deep brain stimulation for OCD? Data from a naturalistic clinical sample. J Neuropsychiatry Clin Neurosci. 2014; 26(1):81-6.
    View in: PubMed
    Score: 0.005
  104. Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav Res Ther. 2013 Dec; 51(12):823-9.
    View in: PubMed
    Score: 0.005
  105. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jun; 74(6):e527-32.
    View in: PubMed
    Score: 0.005
  106. Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety. 2013 Aug; 30(8):716-22.
    View in: PubMed
    Score: 0.004
  107. The relationship between insight and control in obsessive-compulsive disorder: implications for the insanity defense. Bull Am Acad Psychiatry Law. 1993; 21(2):245-52.
    View in: PubMed
    Score: 0.004
  108. A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013 Jan; 70(1):85-94.
    View in: PubMed
    Score: 0.004
  109. Rebound symptoms following battery depletion in the NIH OCD DBS cohort: clinical and reimbursement issues. Brain Stimul. 2012 Oct; 5(4):599-604.
    View in: PubMed
    Score: 0.004
  110. Cerebral laterality, perception of emotion, and treatment response in obsessive-compulsive disorder. Biol Psychiatry. 1991 May 01; 29(9):900-8.
    View in: PubMed
    Score: 0.004
  111. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010 Dec 01; 68(11):1073-6.
    View in: PubMed
    Score: 0.004
  112. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord. 1990 Dec; 20(4):537-43.
    View in: PubMed
    Score: 0.004
  113. Refining clinical judgment of treatment outcome in obsessive-compulsive disorder. Psychiatry Res. 2011 Feb 28; 185(3):394-401.
    View in: PubMed
    Score: 0.004
  114. Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. Psychiatry Res. 2010 Aug 15; 178(3):467-74.
    View in: PubMed
    Score: 0.004
  115. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990 Jun; 47(6):577-85.
    View in: PubMed
    Score: 0.004
  116. Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder. Neuroimage. 2011 Jan; 54 Suppl 1:S247-55.
    View in: PubMed
    Score: 0.004
  117. Lack of benefit of accumbens/capsular deep brain stimulation in a patient with both tics and obsessive-compulsive disorder. Neurocase. 2010 Aug; 16(4):321-30.
    View in: PubMed
    Score: 0.004
  118. Cognitive behavioral therapy plus motivational interviewing improves outcome for pediatric obsessive-compulsive disorder: a preliminary study. Cogn Behav Ther. 2010; 39(1):24-7.
    View in: PubMed
    Score: 0.004
  119. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989 Nov; 46(11):1012-6.
    View in: PubMed
    Score: 0.004
  120. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989 Nov; 46(11):1006-11.
    View in: PubMed
    Score: 0.004
  121. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord. 2010 Feb; 121(1-2):175-9.
    View in: PubMed
    Score: 0.003
  122. Children's Florida Obsessive Compulsive Inventory: psychometric properties and feasibility of a self-report measure of obsessive-compulsive symptoms in youth. Child Psychiatry Hum Dev. 2009 Sep; 40(3):467-83.
    View in: PubMed
    Score: 0.003
  123. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989 Jan; 46(1):36-44.
    View in: PubMed
    Score: 0.003
  124. Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder. Depress Anxiety. 2009; 26(1):E23-5.
    View in: PubMed
    Score: 0.003
  125. Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2008 Jul; 47(7):763-772.
    View in: PubMed
    Score: 0.003
  126. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010 Jan; 15(1):64-79.
    View in: PubMed
    Score: 0.003
  127. Associations between miscellaneous symptoms and symptom dimensions in adults with obsessive-compulsive disorder. Anxiety Stress Coping. 2008 Apr; 21(2):199-212.
    View in: PubMed
    Score: 0.003
  128. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.003
  129. Convergent and discriminant validity of the Children's Yale-Brown Obsessive Compulsive Scale-Symptom Checklist. J Anxiety Disord. 2008 Dec; 22(8):1369-76.
    View in: PubMed
    Score: 0.003
  130. Obsessive-compulsive disorder in youth with and without a chronic tic disorder. Depress Anxiety. 2008; 25(9):761-7.
    View in: PubMed
    Score: 0.003
  131. Clinical features associated with treatment-resistant pediatric obsessive-compulsive disorder. Compr Psychiatry. 2008 Jan-Feb; 49(1):35-42.
    View in: PubMed
    Score: 0.003
  132. A measure of functional impairment in youth with Tourette's syndrome. J Pediatr Psychol. 2007 Sep; 32(8):950-9.
    View in: PubMed
    Score: 0.003
  133. Family accommodation in pediatric obsessive-compulsive disorder. J Clin Child Adolesc Psychol. 2007 Apr-Jun; 36(2):207-16.
    View in: PubMed
    Score: 0.003
  134. Quality of life in youth with Tourette's syndrome and chronic tic disorder. J Clin Child Adolesc Psychol. 2007 Apr-Jun; 36(2):217-27.
    View in: PubMed
    Score: 0.003
  135. Further psychometric examination of the Tourette's Disorder Scales. Child Psychiatry Hum Dev. 2007 Aug; 38(2):89-98.
    View in: PubMed
    Score: 0.003
  136. Relationship of movements and behaviors to Group A Streptococcus infections in elementary school children. Biol Psychiatry. 2007 Feb 01; 61(3):279-84.
    View in: PubMed
    Score: 0.003
  137. Peer victimization in children with obsessive-compulsive disorder: relations with symptoms of psychopathology. J Clin Child Adolesc Psychol. 2006 Sep; 35(3):446-55.
    View in: PubMed
    Score: 0.003
  138. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Nov; 31(11):2384-93.
    View in: PubMed
    Score: 0.003
  139. Cognitive-behavioral treatment for obsessive-compulsive disorder in an elderly male with concurrent medical constraints. Am J Geriatr Psychiatry. 2006 Apr; 14(4):380-1.
    View in: PubMed
    Score: 0.003
  140. Reliability and validity of the Child Behavior Checklist Obsessive-Compulsive Scale. J Anxiety Disord. 2006; 20(4):473-85.
    View in: PubMed
    Score: 0.003
  141. Assessment of pediatric obsessive-compulsive disorder: a critical review of current methodology. Child Psychiatry Hum Dev. 2005; 36(2):195-214.
    View in: PubMed
    Score: 0.003
  142. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry. 2004 Jun; 65(6):742-9.
    View in: PubMed
    Score: 0.002
  143. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003 Jun; 64(6):640-7.
    View in: PubMed
    Score: 0.002
  144. Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Sep; 15(3):159-75.
    View in: PubMed
    Score: 0.002
  145. Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry. 2002 Feb; 159(2):263-8.
    View in: PubMed
    Score: 0.002
  146. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001 Feb; 21(1):46-52.
    View in: PubMed
    Score: 0.002
  147. Segregation analysis of obsessive-compulsive disorder using symptom-based factor scores. Am J Med Genet. 1999 Dec 15; 88(6):669-75.
    View in: PubMed
    Score: 0.002
  148. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry. 1999 May; 60(5):346-51; quiz 352.
    View in: PubMed
    Score: 0.002
  149. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res. 1999 Mar 22; 85(3):225-40.
    View in: PubMed
    Score: 0.002
  150. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology. 1999 Jan; 24(1):1-24.
    View in: PubMed
    Score: 0.002
  151. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997 Sep; 154(9):1293-5.
    View in: PubMed
    Score: 0.002
  152. Symptoms of obsessive-compulsive disorder. Am J Psychiatry. 1997 Jul; 154(7):911-7.
    View in: PubMed
    Score: 0.002
  153. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997 Jun; 36(6):844-52.
    View in: PubMed
    Score: 0.001
  154. Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry. 1997 May 01; 41(9):949-54.
    View in: PubMed
    Score: 0.001
  155. B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Am J Psychiatry. 1997 Mar; 154(3):402-7.
    View in: PubMed
    Score: 0.001
  156. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry. 1997 Jan 01; 41(1):117-21.
    View in: PubMed
    Score: 0.001
  157. High doses of sertraline for treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1996 Sep; 153(9):1232-3.
    View in: PubMed
    Score: 0.001
  158. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry. 1996 May 01; 39(9):776-83.
    View in: PubMed
    Score: 0.001
  159. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995 Dec; 152(12):1812-4.
    View in: PubMed
    Score: 0.001
  160. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biol Psychiatry. 1995 Jul 15; 38(2):74-85.
    View in: PubMed
    Score: 0.001
  161. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry. 1995 May; 152(5):772-7.
    View in: PubMed
    Score: 0.001
  162. Family accommodation in obsessive-compulsive disorder. Am J Psychiatry. 1995 Mar; 152(3):441-3.
    View in: PubMed
    Score: 0.001
  163. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology. 1995 Feb; 12(1):73-86.
    View in: PubMed
    Score: 0.001
  164. A family study of obsessive-compulsive disorder. Am J Psychiatry. 1995 Jan; 152(1):76-84.
    View in: PubMed
    Score: 0.001
  165. DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry. 1995 Jan; 152(1):90-6.
    View in: PubMed
    Score: 0.001
  166. Effects of tryptophan depletion in panic disorder. Biol Psychiatry. 1994 Dec 01; 36(11):775-7.
    View in: PubMed
    Score: 0.001
  167. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry. 1994 Oct; 51(10):782-92.
    View in: PubMed
    Score: 0.001
  168. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994 Jul; 51(7):559-67.
    View in: PubMed
    Score: 0.001
  169. "Just right" perceptions associated with compulsive behavior in Tourette's syndrome. Am J Psychiatry. 1994 May; 151(5):675-80.
    View in: PubMed
    Score: 0.001
  170. Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. Br J Psychiatry. 1994 Apr; 164(4):469-73.
    View in: PubMed
    Score: 0.001
  171. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr; 51(4):302-8.
    View in: PubMed
    Score: 0.001
  172. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994 Apr; 51(4):309-17.
    View in: PubMed
    Score: 0.001
  173. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry. 1994 Mar; 55 Suppl:24-31.
    View in: PubMed
    Score: 0.001
  174. Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety. 1994-1995; 1(5):208-15.
    View in: PubMed
    Score: 0.001
  175. Inpatient treatment of patients with severe obsessive-compulsive disorder. Hosp Community Psychiatry. 1993 Dec; 44(12):1150-4.
    View in: PubMed
    Score: 0.001
  176. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol. 1993 Oct; 13(5):354-8.
    View in: PubMed
    Score: 0.001
  177. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 1993 Aug; 48(2):119-33.
    View in: PubMed
    Score: 0.001
  178. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993 Apr; 150(4):647-9.
    View in: PubMed
    Score: 0.001
  179. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992 Jul; 31(4):746-50.
    View in: PubMed
    Score: 0.001
  180. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991 Jun; 11(3):175-84.
    View in: PubMed
    Score: 0.001
  181. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry. 1990 Nov; 157:762-5.
    View in: PubMed
    Score: 0.001
  182. Low CSF 5HIAA and obsessions of violence: report of two cases. Psychiatry Res. 1990 Jul; 33(1):95-9.
    View in: PubMed
    Score: 0.001
  183. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1990 May; 147(5):652-4.
    View in: PubMed
    Score: 0.001
  184. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990; 26(3):279-84.
    View in: PubMed
    Score: 0.001
  185. Pathophysiology of obsessive-compulsive disorder. Am J Psychiatry. 1989 Oct; 146(10):1350-1.
    View in: PubMed
    Score: 0.001
  186. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988 Feb; 45(2):177-85.
    View in: PubMed
    Score: 0.001
  187. Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry. 1988 Jan; 45(1):43-52.
    View in: PubMed
    Score: 0.001
  188. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry. 1987 Aug; 144(8):1030-6.
    View in: PubMed
    Score: 0.001
  189. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry. 1987 Aug; 144(8):1059-61.
    View in: PubMed
    Score: 0.001
  190. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology (Berl). 1987; 93(3):308-13.
    View in: PubMed
    Score: 0.001
  191. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl). 1987; 92(1):14-24.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.